The new Eurosurveillance website is almost here.

Eurosurveillance is on the updated list of the Directory of Open Access Journals and in the SHERPA/RoMEO database. Read more here.

On 6 June 2017, the World Health Organization (WHO) published updates to its ‘Essential Medicines List’ (EML). Read more here.

Follow Eurosurveillance on Twitter: @Eurosurveillanc

In this issue

Home Eurosurveillance Edition  2010: Volume 15/ Issue 40 Article 1
Back to Table of Contents
Download (pdf)

Eurosurveillance, Volume 15, Issue 40, 07 October 2010
Rapid communications
Dengue virus infection in a traveller returning from Croatia to Germany
  1. Bernhard Nocht Institute for Tropical Medicine, Department of Virology, Hamburg, Germany
  2. Labor Hannover MVZ GmbH, Hannover, Germany
  3. Robert Koch Institute, Department for Infectious Disease Epidemiology, Berlin, Germany

Citation style for this article: Schmidt-Chanasit J, Haditsch M, Schöneberg I, Günther S, Stark K, Frank C. Dengue virus infection in a traveller returning from Croatia to Germany. Euro Surveill. 2010;15(40):pii=19677. Available online:
Date of submission: 01 October 2010

Dengue virus (DENV) is endemic in south-east Asia and Central to South America. In August 2010, a DENV infection was diagnosed in a German traveller returning from a trip to Croatia in south-east Europe. The patient presented with fever and other typical symptoms of DENV-infection. Virological investigation revealed the presence of DENV-specific IgM, a rise in DENV-specific IgG and the presence of DENV NS1 antigen in the patient’s blood.

Dengue virus (DENV) is an arthropod-borne RNA virus of the Flaviviridae family causing dengue fever in humans. Since 2001 dengue fever has been mandatorily reported to the German public health authorities, in accordance with the Federal Protection against Infection Act [1]. According to German notification data, between 60 and 387 imported DENV infections are reported annually (Table).

Table. Imported cases of dengue fever per year, Germany, 2001–2010a

The DENV infections in imported cases are mainly acquired in south-east Asia as well as South and Central America. Very recently, autochthonous DENV infections were reported in southern France, diagnosed for the first time ever in Europe [2]. Here we report on a case of DENV infection that was apparently acquired in Croatia and imported to Germany by a traveller.

Case report

A 72-year-old man from Germany visited Croatia in August 2010: he left on 1 August and returned on 15 August. He was accompanied by seven family members, including grandchildren. The family travelled by car from Germany via Austria and Slovenia to Croatia without overnight stops. The group stayed the entire time around Podobuce close to Orebić on the Peljesac peninsula and on the isle of Korčula in the south of Croatia. Podobuce and Korčula are located approximately 100 km north-west of the city of Dubrovnik, which was also visited. Temperatures were reported to be very high (approximately 30 °C at night). After returning to Germany, on 16 August, the patient developed a febrile illness with a temperature of up to 39 °C, chills, arthralgia, headache, and retro-orbital pain. Following a short period of improvement, his temperature rose again to 39 °C on 21 August, and he continued to have arthralgia, myalgia, weakness and dyspnoea. Among several other diseases, dengue fever was suspected by the general practitioner, because of the clinical picture.

Laboratory results

Serum samples were taken from the patient for virological investigation on 23 and 30 August and on 2 September. The sample from 23 August was positive for DENV-specific IgM, but negative for IgG in an enzyme-linked immunosorbent assay (ELISA). On 30 August, DENV-specific IgM and IgG was positive with a titre of 1:2,560 (cut-off 1:20) and 1:80 (cut-off 1:20), respectively, in an indirect immunofluorescence assay based on DENV-infected cells. In addition, the serum sample tested positive for DENV NS1 antigen (Dengue Early ELISA, Panbio). Real-time reverse transcription-polymerase chain reaction (RT-PCR) for DENV [3] was negative. The detection of DENV NS1 antigen and the simultaneous absence of DENV RNA during this phase of dengue fever are in line with previous studies demonstrating an acute DENV infection [4]. The sample taken on 2 September showed an  increase in the DENV-specific IgG titre (1:1,280), while the IgM titre remained unchanged and the ELISA for NS1 antigen was negative. In this sample, immunofluorescence assay titres for related flaviviruses were lower than for DENV: West Nile virus (IgM negative, IgG 1:160) and tick-borne encephalitis virus (IgM 1:80, IgG 1:80). The patient did not report vaccination against tick-born encephalitis or yellow fever. A temporary thrombocytopenia with a minimal platelet count of 97,000/µl (norm: 150,000–440,000/µl) on the eighth day of the illness resolved without complications and the patient recovered within two weeks after disease onset.


The clinical suspicion of dengue fever was confirmed by the laboratory tests. As the incubation period for dengue fever ranges from three to 14 days , the infection was probably acquired in southern Croatia and not en route. The Croatian authorities were given all available information about the case, enabling them to investigate this further at local level. To our knowledge, this is the second report on an autochthonous DENV transmission in Europe after France. Antibodies against DENV have been previously detected in Croatian individuals in the context of international travel; however, the specificity of the assay is questionable [5]. The presence of Aedes albopictus as a potential DENV vector in Croatia [6] and the importation of confirmed dengue fever cases from endemic areas into Croatia [7,8] allow autochthonous DENV transmission within this country. The mosquito season in parts of the northern Mediterranean coast may last from May to November. Therefore, dengue fever should be considered in patients with fever of unknown origin and relevant clinical symptoms who stayed in areas in Europe where Ae. albopictus occurs.
We thank M. Reichmann, B. Noack, S. Kunstmann, P. Emmerich, B. Braunsdorf and B.Hiller for preparation of additional clinical, laboratory and epidemiological data related to this case.


  1. Dreesman J, Benzler J. [Infectious disease surveillance based on the Protection against Infection Act in the German public health sector]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2005;48(9):979-89. German
  2. La Ruche G, Souarès Y, Armengaud A, Peloux-Petiot F, Delaunay P, Desprès P, et al. First two autochthonous dengue virus infections in metropolitan France, September 2010. Euro Surveill. 2010;15(39):pii=19676. Available from:
  3. Drosten C, Göttig S, Schilling S, Asper M, Panning M, Schmitz H, Günther S. Rapid detection and quantification of RNA of Ebola and Marburg viruses, Lassa virus, Crimean-Congo hemorrhagic fever virus, Rift Valley fever virus, dengue virus, and yellow fever virus by real-time reverse transcription-PCR. J Clin Microbiol. 2002;40(7):2323-30.
  4. Schilling S, Emmerich P, Günther S, Schmidt-Chanasit J. Dengue and Chikungunya virus co-infection in a German traveller. J Clin Virol. 2009;45(2):163-4.
  5. Ropac D, Gould E, Punda V, Vesenjak-Hirjan J. [Dengue viruses in northeastern Croatia]. Lijec Vjesn. 1988;110(6-7):177-80. Croatian.
  6. Klobucar A, Merdic E, Benic N, Baklaic Z, Krcmar S. First record of Aedes albopictus in Croatia. J Am Mosq Control Assoc. 2006;22(1):147-8.
  7. Markotic A, Betica Radic L, Maretic T. [Viral tourism: dengue virus]. Croatian Journal of Infection. 2007; 27(4):181-4. Croatian.
  8. Pinazo MJ, Muñoz J, Betica L, Maretic T, Zekan S, Avsic-Zupanc T, et al. Imported dengue hemorrhagic fever, Europe. Emerg Infect Dis. 2008;14(8):1329-30.

Back to Table of Contents
Download (pdf)

The publisher’s policy on data collection and use of cookies.

Disclaimer: The opinions expressed by authors contributing to Eurosurveillance do not necessarily reflect the opinions of the European Centre for Disease Prevention and Control (ECDC) or the editorial team or the institutions with which the authors are affiliated. Neither ECDC nor any person acting on behalf of ECDC is responsible for the use that might be made of the information in this journal. The information provided on the Eurosurveillance site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Our website does not host any form of commercial advertisement. Except where otherwise stated, all manuscripts published after 1 January 2016 will be published under the Creative Commons Attribution (CC BY) licence. You are free to share and adapt the material, but you must give appropriate credit, provide a link to the licence, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

Eurosurveillance [ISSN] - ©2007-2016. All rights reserved

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.